Latest Period
Q4 2025
Security Snapshot
Beam Therapeutics Inc. - Common Stock (BEAM) Institutional Ownership
CUSIP: 07373V105
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
242
Shares (Excl. Options)
106,809,397
Price
$27.72
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- BEAM on Nasdaq
- Shares outstanding
- 100,548,635
- Price per share
- $23.83
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 106,809,397
- Total reported value
- $2,961,239,917
- % of total 13F portfolios
- 0%
- Share change
- +221,456
- Value change
- +$15,891,836
- Number of holders
- 242
- Price from insider filings
- $23.83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BEAM - Beam Therapeutics Inc. - Common Stock is tracked under CUSIP 07373V105.
- 242 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 242 to 29 between Q4 2025 and Q1 2026.
- Reported value moved from $2,961,239,917 to $17,814,121.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 242 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 07373V105?
CUSIP 07373V105 identifies BEAM - Beam Therapeutics Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 07373V105:
Significant Owners of Beam Therapeutics Inc. - Common Stock (BEAM) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | -7.1% | $353,440,240 | -$28,167,623 | 12,750,369 | -7.4% | FMR LLC | 31 Dec 2025 |
| ARK Investment Management LLC | 12% | +19% | $345,590,479 | +$57,021,481 | 12,467,189 | +20% | ARK Investment Management LLC | 31 Dec 2025 |
| Farallon Capital Partners, L.P. | 10% | 0% | $281,132,248 | +$4,681,243 | 10,141,856 | +1.7% | Dapice Joshua J. | 31 Dec 2025 |
| BlackRock, Inc. | 7.5% | $147,823,620 | 7,499,930 | BlackRock, Inc. | 31 Mar 2025 | |||
| STATE STREET CORP | 5.2% | $144,934,824 | 5,228,529 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| ARCH Venture Fund IX, L.P. | 4.6% | -17% | $90,680,723 | 4,600,747 | 0% | Robert Nelsen | 31 Mar 2025 |
As of 31 Dec 2025, 242 institutional investors reported holding 106,809,397 shares of Beam Therapeutics Inc. - Common Stock (BEAM). This represents 106% of the company’s total 100,548,635 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Beam Therapeutics Inc. - Common Stock (BEAM) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | 12,467,189 | +13% | 2.3% | $345,590,488 |
| FMR LLC | 12% | 11,909,138 | +1.8% | 0.02% | $330,121,317 |
| FARALLON CAPITAL MANAGEMENT LLC | 10% | 10,063,111 | 0% | 1.6% | $278,949,437 |
| VANGUARD GROUP INC | 9.1% | 9,193,474 | -0.62% | 0% | $254,843,099 |
| BlackRock, Inc. | 8.4% | 8,450,182 | +3.7% | 0% | $234,239,046 |
| STATE STREET CORP | 5.2% | 5,228,529 | +30% | 0% | $144,934,824 |
| ARCH Venture Management, LLC | 4.5% | 4,540,132 | 0% | 19% | $125,852,459 |
| Amova Asset Management Americas, Inc. | 4.4% | 4,409,300 | -8.7% | 1.4% | $122,181,703 |
| Sumitomo Mitsui Trust Group, Inc. | 4.4% | 4,409,300 | -8.7% | 0.07% | $122,225,796 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 2,730,282 | +21% | 0.01% | $75,684,000 |
| Kynam Capital Management, LP | 2.4% | 2,440,214 | -3.1% | 4.4% | $67,642,732 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,351,908 | -1.6% | 0% | $65,206,279 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 1,947,879 | +13% | 0.01% | $53,995,738 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.7% | 1,712,359 | +2.8% | 0.01% | $47,466,591 |
| Casdin Capital, LLC | 1.6% | 1,600,000 | 0% | 2.8% | $44,352,000 |
| Redmile Group, LLC | 1.3% | 1,285,859 | -7.3% | 2.6% | $35,644,011 |
| MWG Caph Ltd | 1.3% | 1,266,934 | 0% | 49% | $35,119,410 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 1,120,389 | +196% | 0.05% | $31,057,183 |
| Woodline Partners LP | 0.99% | 993,066 | +82% | 0.11% | $27,527,790 |
| UBS Group AG | 0.97% | 973,843 | -14% | 0.01% | $26,994,928 |
| MARSHALL WACE, LLP | 0.94% | 945,829 | 0.03% | $26,218,379 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.83% | 834,795 | -0.76% | 0% | $23,140,517 |
| NORTHERN TRUST CORP | 0.8% | 808,947 | -5.3% | 0% | $22,424,012 |
| MORGAN STANLEY | 0.73% | 729,400 | +13% | 0% | $20,218,979 |
| JPMORGAN CHASE & CO | 0.62% | 619,241 | +14% | 0% | $17,165,361 |
Institutional Holders of Beam Therapeutics Inc. - Common Stock (BEAM) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 774,092 | $17,814,121 | -$4,246,194 | $23.83 | 29 |
| 2025 Q4 | 106,809,397 | $2,961,239,917 | +$15,891,836 | $27.72 | 242 |
| 2025 Q3 | 106,531,653 | $2,585,329,209 | -$9,441,913 | $24.27 | 214 |
| 2025 Q2 | 108,325,993 | $1,842,599,951 | +$102,159,924 | $17.01 | 213 |
| 2025 Q1 | 101,329,623 | $1,984,124,636 | +$387,248,348 | $19.53 | 234 |
| 2024 Q4 | 81,429,029 | $2,019,888,804 | +$52,922,730 | $24.80 | 228 |
| 2024 Q3 | 78,929,001 | $1,933,839,851 | +$32,128,779 | $24.50 | 217 |
| 2024 Q2 | 77,540,507 | $1,816,892,862 | +$138,460,483 | $23.43 | 210 |
| 2024 Q1 | 70,332,894 | $2,323,064,829 | +$51,308,447 | $33.04 | 217 |
| 2023 Q4 | 68,925,790 | $1,876,215,663 | +$46,457,918 | $27.22 | 183 |
| 2023 Q3 | 67,439,160 | $1,621,864,483 | +$72,305,572 | $24.05 | 190 |
| 2023 Q2 | 64,198,552 | $2,049,551,170 | +$123,991,732 | $31.93 | 191 |
| 2023 Q1 | 60,372,846 | $1,848,161,788 | +$134,989,244 | $30.62 | 205 |
| 2022 Q4 | 55,910,182 | $2,186,652,051 | +$42,258,811 | $39.11 | 205 |
| 2022 Q3 | 54,633,598 | $2,601,918,929 | -$6,231,369 | $47.64 | 214 |
| 2022 Q2 | 54,764,598 | $2,088,902,541 | +$192,782,034 | $38.71 | 191 |
| 2022 Q1 | 49,225,196 | $2,820,671,022 | +$201,996,007 | $57.30 | 230 |
| 2021 Q4 | 45,547,893 | $3,629,719,477 | -$39,454,291 | $79.69 | 224 |
| 2021 Q3 | 45,176,306 | $3,933,867,577 | -$43,842,015 | $87.01 | 223 |
| 2021 Q2 | 45,484,033 | $5,854,372,685 | +$342,578,385 | $128.71 | 223 |
| 2021 Q1 | 43,012,900 | $3,436,702,468 | +$478,571,473 | $80.04 | 203 |
| 2020 Q4 | 36,917,618 | $3,014,269,128 | +$632,622,766 | $81.64 | 152 |
| 2020 Q3 | 29,525,955 | $726,945,347 | +$39,624,702 | $24.62 | 84 |
| 2020 Q2 | 27,707,853 | $775,554,484 | +$34,103,632 | $28.00 | 70 |
| 2020 Q1 | 26,888,544 | $483,990,454 | +$483,990,450 | $18.00 | 60 |